Acknowledgements We extend our sincere gratitude to Prof
Lundgren JR, Janus C, Jensen SB, Juhl CR, Olsen LM, Christensen RM, et al
By using Doctronic.ai, patients can avoid the risks associated with grey market drugs and have peace of mind knowing their treatment is supervised by qualified healthcare providers
And when Breakthrough Therapy Designation (BTD) is granted, outcomes can be meaningful: a decade-long analysis reported ~72% of BTD-designated drugs ultimately achieved FDA approval (with additional programs still pending decisions)
In one clinical trial, 1,961 participants experienced an average weight loss of 14.9% after taking 2.4mg of semaglutide for 68 weeks: Other studies demonstrate varying amounts lost, usually over six months to 68 weeks